Analyst Coverage

Disclaimer: Any opinions, estimates or forecasts regarding ResApp Health Limited’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResApp Health Limited or its management. ResApp Health Limited does not by its reference to any analysts imply its endorsement of or concurrence with such information, conclusions or recommendations.

Morgans Financial August 28, 2019 CE mark for children’s diagnostic a RAP
Bioshares August 26, 2019 ResApp Gains First Regulatory Clearance for Pediatric Diagnostic
Morgans Financial July 31, 2019 Critical six months ahead
Morgans Financial April 30, 2019 Plenty ahead to maintain momentum
Morgans Financial April 23, 2019 Breathe Easy delivers
Bioshares April 1, 2019 ResApp Reports Updated Results from US Pediatric Study
Morgans Financial March 18, 2019 Croup too rare to show significance
Morgans Financial February 28, 2019 Focus remains on study results
Bioshares February 11, 2019 Q3 FDA Filing for ResAppDx
Morgans Financial January 3, 2019 Short term catalysts to play
Morgans Financial November 1, 2018 Over reaction
Morgans Financial September 3, 2018 Big RAPs
Morgans Financial August 2, 2018 Key catalyst imminent
Bioshares July 16, 2018 ResApp to Report Outcomes from Multiple Trials in Coming Months
Morgans Financial May 9, 2018 Key results approach
Morgans Financial March 1, 2018 Focused on trial results in 3QCY18
Morgans Financial January 8, 2018 Key milestone achieved with trial start
Bioshares September 18, 2017 ResApp Tightens Up Study Protocol for Repeat US Study
Morgans Financial September 1, 2017 Waiting for trial restart
Bioshares August 11, 2017 Learnings for ResApp from US Pediatric Study
Morgans Financial August 9, 2017 Endpoints not met
Morgans Financial July 7, 2017 What’s in a cough
NDF Research June 30, 2017 First major clinical study of ResAppDx reports important data
Patersons Securities June 9, 2017 Market Update
Patersons Securities March 1, 2017 1H17 Result, Waiting on FDA Trial Data
Patersons Securities November 16, 2016 Initiating Coverage
Bioshares August 19, 2016 Telemedicine Adoption Building
NDF Research July 25, 2016 Initiation of Coverage
DJ Carmichael April 4, 2016 Emerging ASX Technology Sector
DJ Carmichael October 19, 2015 Emerging ASX Technology Sector
Bioshares October 9, 2015 Good Early Data for ResApp
Bioshares August 28, 2015 TeleMedicine is on the Move

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.